tbuckley/cabot-search huggingface dataset:
Leucovorin rescue revisited.
Authors: J R Bertino
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.2.193 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2299365 Leucovorin rescue revisited. J R BertinoxJ R BertinoSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.2.193 First Page PDF © 1990 by American Society of Clinical Oncology
Abstract 12334: A Flavor of Metabolic Disease in Pulmonary Hypertension
Authors: Aurelie Hautefort, Julie Chesne, Jens Preussner, Jorg Tost, Mario Looso, Fabrice Antigny, David Montani, Jean-François Deleuze, Werner Seeger, Elie Fadel, Gerald Simonneau, Sebastien Bonnet, Marc Humbert, Frederic Perros
Journal: Circulation (2015)

Introduction: Pulmonary arterial hypertension (PAH) is a severe occlusive vascular disease of the lungs. One of the primary origin of PAH is pulmonary endothelial dysfunction driving vasoconstriction, aberrant angiogenesis and smooth muscle cell proliferation, endothelial-to-mesenchymal transition, thrombosis and inflammation. Interestingly, endothelial dysfunction is maintained in culture, out of fluid and hemodynamic stress, humoral/hormonal, and inflammatory environment. Hypothesis: This aberrant phenotype may be imprinted in pulmonary endothelial cells (PEC) DNA though a specific pattern of DNA methylations. Methods: Genomic DNA was extracted from cultured PEC (passage 3): idiopathic PAH (n=11), heritable PAH (BMPR2 mutation carriers, n=10), controls (n=18). DNA methylation was assessed at over 485 000 CpG sites using the Illumina Infinium HumanMethylation450 Bead Chip. We normalized all arrays against each other using functional normalization. Differentially methylated sites were clustered with Cluster3.0 and heatmap were obtained with Treeview. Results: We discriminated controls vs PAH into 2 clusters of hypermethylated loci (119 probes= 31 promoters) and hypomethylated loci (331 probes= 116 promoters). Interestingly, 46 promoters/147 (clusters 1+2) (31%) were related to metabolic diseases (Ingenuity pathway analysis), and top molecules (fold changes up- and down regulated) includes molecules highly involved in cellular lipid metabolic process (ABCA1, Q=0.002 and ABCB4, Q=0.003), regulation of glucogenesis (ACN9, Q=2.78.10-5), lipid and glucose metabolism (ADIPOQ, Q=10-4), and insulin sensitivity and metabolism of glucose and lipids (miR-26a, Q=0.005), among others. Conclusions: the methylation fingerprint of PAH highlighted a set of molecules involved in metabolic disease and metabolism regulation. This may have fundamental and clinical implications in PAH.
Body surface mapping for the assessment of left ventricular hypertrophy in patients with essential hypertension.
Authors: Hide Igarashi, Isao Kubota, Kozue Ikeda, Michiyasu Yamaki, Kai Tsuiki, Shoji Yasui
Journal: Circulation (1987)

To investigate the electrocardiographic abnormalities of left ventricular hypertrophy (LVH), body surface potential maps were acquired from 42 patients with essential hypertension. We adopted the time integral technique for analyzing body surface mapping data and used echocardiographic left ventricular muscle mass (LV mass) as the index of advance of LVH. The QRS, STAT and QRST isointegral maps in normal volunteers all demonstrated smooth bipolar surface distribution patterns, with positive values located over the precordium and negative values over the right upper chest and back. In patients with essential hypertension, changes in the isointegral maps were observed as LVH advanced; A^- QRS increased on the upper left lateral chest and decreased (became more negative) on the right chest, A^- STAT decreased on the lower left lateral chest and increased on the right upper chest, and areas of significant difference in A^- QRS and A^- STAT were expanded as LVH advanced. A^- QRST decreased on the lower left lateral chest and increased on the right upper chest only in patients with severe LVH. We conclude that the changes of QRS and STAT isointegral maps depend on the degree of advance of LVH and the severe grade of LVH causes the alterations in intrinsic repolarization properties.
A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503
Authors: K. Kubota, H. Kunitoh, T. Seto, N. Shimada, M. Tsuboi, H. Okamoto, N. Masuda, R. Maruyama, M. Shibuya, K. Watanabe
Journal: Journal of Clinical Oncology (2009)

7561 Background: Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC. However, the optimum chemotherapy regimen has not been determined. TORG 0503 was conducted to evaluate platinum-based third generation regimens in this clinical setting. Methods: Patients with completely resected stage IB, IIA, IIB or stage IIIA NSCLC were stratified by stage (IB/IIA vs. IIB/IIIA) and institution and randomized to receive 3 cycles of DOC (60 mg/m2, day 1) plus CIS (80 mg/m2, day 1) or 3 cycles of PAC (200 mg/m2, day 1) plus CAR (AUC 6, day 1). Both regimens were repeated every 3 - 4 weeks. Other eligibility criteria included ECOG PS 0–1, age ≥20, and =&lt;70 years old, adequate organ function, no prior chemotherapy or radiotherapy. Patients who underwent pneumonectomy were excluded. The primary endpoint was 2-year relapse free survival (RFS), and secondary endpoints were overall survival (OS), quality of life (QOL), feasibility and toxicity. Results: 111 patients were randomized between April 2006 and July 2008, 58 patients to DOC+CIS (DC) and 53 to PAC+CAR (PA). Patients’ demographics (DC/PA): median age 63/59 years, 60%/66% male, 17%/22% PS 1, 79%/73% adenocarcinoma, 40%/40% of patients were stage IB/IIA, 60%/60% IIB/IIIA. Feasibility: 93% (54/58) of patients allocated to DC and 92% (49/53) patients in the PA arm completed 3 planned cycles of chemotherapy. Toxicities: DC vs. PA: Grade (G) 3/4 neutropenia (86%/75%), G3/4 anemia (2%/0%). G 3 febrile neutropenia (10%/4%), G2 ALT (0%/10%), G2 creatinine (17%/0%), G2–4 allergy (0%/4%), G2 alopecia (43%/47%), G2/3 fatigue (5%/10%), G2/3 anorexia (43%/22%), G2/3 nausea (47%/22%), G2/3 vomiting (31%/12%), G2 diarrhea (12%/8%), G2 constipation (2%/4%), G2/3 sensory neuropathy (3%/33%), G2/3 arthralgia (0%/31%), G2 myalgia (2%/8%). No treatment related deaths were observed in either arm. Conclusions: Both docetaxel plus cisplatin and paclitaxel plus carboplatin are safe and feasible regimens as adjuvant chemotherapy. [Table: see text]
Assessing endotoxemia in alcoholic hepatitis
Authors: Tetsuji Fujita
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. To the Editor: In the September 2015 issue of hepatology, Dr. Michelena and colleagues published a commendable study, in which a serum endotoxin level of more than 1.3 endotoxin units (EUs)/mL at admission predicted the development of in‐hospital infections, nonresponsiveness to corticosteroid therapy, and a high mortality in a subgroup of 50 patients with alcoholic hepatitis.1 As mentioned in the article, the results should be confirmed in independent studies in order to acquire external validity. Before starting prospective studies, it seems necessary to standardize the measurement of circulating endotoxin levels. Michelena and colleagues measure serum endotoxin levels with the limulus amebocyte lysate (LAL) QCL‐1000 test. According to the manufacturer's guidelines (http://bio.lonza.com/uploads/tx _m waxmarketingmaterial/Lonza_ManualsProduct Instructions_QCL‐1000_Product_Insert.pdf), the QCL‐1000 assay is not intended to detect endotoxemia in humans and may be substituted for the rabbit pyrogenic test for end‐product testing of human and animal parenteral drugs, biological products, and medical devices. The term "EU" indicates the national standard biological activity in the LAL assay, which was determined by the US Food and Drug Administration and other organizations based on the relationship between the LAL and the rabbit pyrogenic test. Although the Food and Drug Administration initially defined 1 EU as the endotoxin activity of 200 pg of a reference standard endotoxin, the conversion ratio is dependent on the source of the endotoxin used for each LAL assay, resulting in being between 1 EU to 20 pg and 1 EU to 500 pg.2 Given these findings, blood endotoxin levels should be shown as picograms per milliliter in future multicenter studies. As mentioned earlier, we should remember that the LAL is not prepared for detection of endotoxemia, but it is intended only for in vitro diagnostic purpose. Endotoxin antagonists,3 antibiotics, plasma proteins, and unknown substances4 in the blood can activate or interfere with the LAL test. The LAL assay is not absolutely specific for endotoxin but can react with some fungal glucans. There are ample opportunities for contamination because endotoxins are ubiquitous in the indoor environment. Given these situations, using multiple measurements of circulating endotoxin seems more feasible than one measurement at admission to assess the severity of endotoxemia due to increased gut permeability and dysbiosis associated with alcoholic hepatitis.
Association Between Vitamin D Status and Cognitive Decline
Authors: Robert H. Howland
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Improving palliative care: A 2x2x2 factorial cluster randomized controlled trial of case conferencing and educational outreach visiting
Authors: A. P. Abernethy, D. C. Currow, T. Shelby-James, H. Williams, G. Roder-Allen, R. Hunt, D. Rowett, A. Esterman, F. May, P. A. Phillips
Journal: Journal of Clinical Oncology (2006)

8517 Background: Evidence-based palliative care service delivery models are needed. General practitioner (GP) and patient-centered case conferences may increase multidisciplinary interaction and enhance patient care. Educational outreach visiting in pain management may empower learners and improve care. Methods: Three interventions were tested against a routine care control in a 2×2×2 cluster factorial randomized controlled trial. Interventions were case conferencing, educational visiting for GPs, and educational visiting for patients. Subjects were adult patients referred to palliative care services in southern Adelaide, Australia, with any pain in the preceding 3 months. Participants were followed longitudinally until death. Main outcomes included performance status (Australian-modified Karnofsky Performance Status (AKPS)) and hospitalization rates. Longitudinal intention-to-treat analyses using cluster-specific methods were conducted. The sample goal was 460. Results: 461 participants were enrolled from 4/02–6/04. Mean age was 71 yrs, 50% were male, 91% had cancer. Mean and median survival was 146 and 87 days; median baseline AKPS was 60%. When participants had AKPS &lt;70 (i.e. required a caregiver) at referral, those randomized to case conferencing or patient education had higher mean performance status than routine care (case conferencing: average daily AKPS, 54.9% vs 46.3%, p=0.0106; patient education: 54.7% vs 46.4%, p=0.0120). GP education did not improve performance status. Both case conferencing and patient education significantly decreased hospitalization rates compared to routine care (case conferencing: least-squares mean number of hospitalizations, 1.4 (standard error (SE) 0.1) vs 1.9 (SE 0.1), p=0.0002; patient education: 1.4 (SE 0.1) vs 1.8 (SE 0.1), p=0.0078). The addition of both interventions decreased hospitalizations to 1.2 (SE 0.1). Conclusion: At a time when declining function and higher healthcare utilization is the norm, palliative care that includes a case conference or patient educational visiting for pain leads to improved performance status and decreased hospitalizations. Patients with deteriorating performance status derive the greatest benefit. No significant financial relationships to disclose.
A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
Authors: Brad H. Rovin, Ronald F. van Vollenhoven, Cynthia Aranow, Carrie Wagner, Robert Gordon, Yanli Zhuang, Stanley Belkowski, Benjamin Hsu
Journal: Arthritis & Rheumatology (2016)

Objective To assess the efficacy and safety of sirukumab, an anti–interleukin‐6 monoclonal antibody, for the treatment of patients with active lupus nephritis (LN). Methods Patients with class III or class IV LN (as determined by renal biopsy within 14 months of randomization) who had persistent proteinuria (&gt;0.5 gm/day) despite receiving immunosuppressive therapy and who were being treated with stable doses of a renin‐angiotensin system blocker were randomized (5:1) to receive treatment with sirukumab at a dose of 10 mg/kg intravenously (n = 21) or placebo (n = 4) every 4 weeks through week 24. The primary end point was the percent reduction in proteinuria (measured as the protein‐to‐creatinine [P:C] ratio in a 12‐hour urine collection) from baseline to week 24. Results Twenty‐five patients were enrolled, of whom 19 (76.0%) completed treatment through week 24 and 6 (24.0%) discontinued the study agent early, with 5 of the 6 discontinuing due to adverse events. At week 24, the median percent change in proteinuria from baseline to week 24 in sirukumab‐treated patients was 0.0% (95% confidence interval −61.8, 39.6). In contrast, the 4 placebo‐treated patients showed an increase in proteinuria (median percent reduction −43.3%) at week 24. Of note, a subset of 5 sirukumab‐treated patients had ≥50% improvement in their P:C ratio through week 28. In the sirukumab group, 47.6% of patients experienced ≥1 serious adverse event through week 40; most were infection‐related. No deaths or malignancies occurred. No serious adverse events were observed in the 4 placebo‐treated patients. Conclusion This proof‐of‐concept study did not demonstrate the anticipated efficacy nor did it demonstrate an acceptable safety profile for sirukumab treatment in this population of patients with active LN receiving concomitant immunosuppressive treatment.
Disseminated Herpes Simplex (Kaposi's Varicelliform Eruption) and the Failure of Penicillin and Aureomycin to Influence Its Course
Authors: Minerva S. Buerk, Harvey Blank
Journal: New England Journal of Medicine (1951)

KRAPOSI'S varicelliform eruption is now known to be a clinical syndrome characterized by a virus infection superimposed on a chronic dermatitis, usually an atopic eczema. The responsible virus is either the herpes-simplex virus or the vaccinia virus. When the etiologic agent is known, the disease is more aptly called "disseminated herpes simplex" or "generalized vaccinia."In the past, these two virus infections of the skin could usually be differentiated only by specialized laboratory procedures, or by the microscopical demonstration in biopsies of early vesicles of the inclusion bodies characteristic of herpes simplex (Lipschütz bodies) or of vaccinia (Guarnieri bodies).1 , 2 , 3 Tzanck . . .
Pharmacologic and Genetic Studies on the Modulatory Effects of Butylated Hydroxytoluene on Mouse Lung Adenoma Formation&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN4"&gt;4&lt;/xref&gt;
Authors: A M Malkinson, D S Beer
Journal: JNCI Journal of the National Cancer Institute (1984)

Food additive butylated hydroxytoluene (BHT) (CAS: 128-37-0; 2,6-di-tert-butyl-p-cresol) can modulate the formation of lung adenomas in mice treated with the carcinogen urethan (CAS: 51-79-6; ethyl ester carbamic acid). An ip injection of BHT administered 6 hours before a single urethan injection decreased the number of tumors formed, whereas six weekly BHT injections following a single urethan dose increased tumor multiplicity. Biotransformation of BHT was apparently required for both prophylaxis and enhancement. Pretreatment of mice with cedrene, which perturbs drug metabolism, prevented both of these BHT activities. Analogues of BHT with different substitutions at position 6 of the phenol ring also affected tumor formation. 2-tert-Butyl-4-methylphenol inhibited, not enhanced, adenoma formation. 2-tert-Butyl-4,6-dimethylphenol (BDMP) (CAS: 1879-09-0; 6-tert-butyl-2,4-xylenol); increased tumor number in A/J but not in the BALB/cByJ mouse strain; its prophylactic activity could not be measured since urethan injection following BDMP treatment was lethal. Thus the presence of an alkyl group at this site on the phenol ring was not required for prophylaxis but was necessary for tumor enhancement. These results were consistent with the possibility that different BHT metabolites were responsible for each effect. Adenoma formation was enhanced by BHT in four strains of mice with a U+ phenotype (susceptible to urethan-induced lung adenomas); these strains were A, BALB/cBy, SWR/J, and RIIIS/J. BHT had no such effect, however, in the U+ strain 129/J. A U+ B- phenotype (urethan inducible but unresponsive to BHT enhancement) also was found among the recombinant inbred lines originally derived from a cross between U+B+ BALB/-cByJ and U-/B- C57BL/6ByJ progenitor strains. This finding showed that the genes determining sensitivity to urethan and to BHT had recombined independently of each other. An inability to metabolize BHT was probably not involved in the B- phenotype, since BHT caused reversible lung damage in the 2 U+B- recombinant inbred lines and strain 129, and biotransformation was required for this effect. These U+B- mice thus can be used to characterize the lung toxic effects of BHT in the absence of its tumor-enhancing activity and will serve as valuable controls in studies on mechanisms of tumor enhancement.
Endoscopic mediastinal debridement for mediastinitis resulting from upper esophageal perforation
Authors: Sadashivayya Soppimath, Srishail Chiniwalar, Basavanandaswami Hartimath, Praveen Padasali
Journal: Endoscopy (2016)

A 57-year-old woman was admitted to the intensive care unit with a 15-day history of sore throat, neck pain, upper backache, and fever following the ingestion of a tablet. Initial conservative management did not resolve the symptoms and a contrast-enhanced computed tomography (CECT) scan of the chest was performed. The scan revealed posterior mediastinitis ([Fig. 1]), secondary to upper esophageal perforation with bilateral pleural effusion. An endoscopic assessment revealed a large perforation just below the cricopharynx in the posterior wall ([Fig. 2]), with discharge of copious amount of pus. Surgical opinion was sought. The patient provided informed consent following explanation of the option of surgical drainage by thoracoscopy if endoscopic debridement was not complete.
Direct Mechanical Stimulation of Stem Cells: A Beating Electromechanically Active Scaffold for Cardiac Tissue Engineering
Authors: Amy Gelmi, Artur Cieslar‐Pobuda, Ebo de Muinck, Marek Los, Mehrdad Rafat, Edwin W. H. Jager
Journal: Advanced Healthcare Materials (2016)

The combination of stem cell therapy with a supportive scaffold is a promising approach to improving cardiac tissue engineering. Stem cell therapy can be used to repair nonfunctioning heart tissue and achieve myocardial regeneration, and scaffold materials can be utilized in order to successfully deliver and support stem cells in vivo. Current research describes passive scaffold materials; here an electroactive scaffold that provides electrical, mechanical, and topographical cues to induced human pluripotent stem cells (iPS) is presented. The poly(lactic-co-glycolic acid) fiber scaffold coated with conductive polymer polypyrrole (PPy) is capable of delivering direct electrical and mechanical stimulation to the iPS. The electroactive scaffolds demonstrate no cytotoxic effects on the iPS as well as an increased expression of cardiac markers for both stimulated and unstimulated protocols. This study demonstrates the first application of PPy as a supportive electroactive material for iPS and the first development of a fiber scaffold capable of dynamic mechanical actuation.
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
Authors: Verena Labenski, Julia D. Suerth, Elke Barczak, Dirk Heckl, Camille Levy, Ornellie Bernadin, Emmanuelle Charpentier, David A. Williams, Boris Fehse, Els Verhoeyen, Axel Schambach
Journal: Biomaterials (2016)
An Official American Thoracic Society Research Statement: Impact of Mild Obstructive Sleep Apnea in Adults
Authors: Susmita Chowdhuri, Stuart F. Quan, Fernanda Almeida, Indu Ayappa, Salma Batool-Anwar, Rohit Budhiraja, Peggy E. Cruse, Luciano F. Drager, Barbara Griss, Nathaniel Marshall, Sanjay R. Patel, Susheel Patil, Shandra L. Knight, James A. Rowley, Alison Slyman
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Executive SummaryContentsOverviewIntroductionPurposeMethodsEvidence SynthesesLimitationsKnowledge GapsResearch RecommendationsConclusionsReferencesCITING ARTICLES
Airway but Not Blood Type 2 Innate Lymphoid Cells (ILC2s) from Asthmatic Patients Are Steroid-Resistant, Which Is Induced By IL7R-Alpha Ligands
Authors: Rafeul Alam, Sucai Liu, Verma Mukesh, Weimin Liu, Magdalena M. Gorska, James Good, Donald Rollins
Journal: Journal of Allergy and Clinical Immunology (2016)